EVERSANA’s Dr. Vivek Ahuja, Senior Vice President, Global Delivery Excellence, Strategy & Growth, PV, Quality & Regulatory Service Lines, will present “Artful Simplification: Transforming Pharmacovigilance” on 5 October at 12:15 CEST.
About EVERSANA’s Integrated Pharmacovigilance Solution
EVERSANA offers an Integrated Pharmacovigilance Solution that blends advanced technology and human interaction to enhance and streamline pharmacovigilance activities. This solution employs automation, artificial intelligence, data analytics, and ACTICS by EVERSANA™ to create an efficient, cost-effective, and compliant experience. It ensures the safety of partners’ product portfolios and patients’ well-being. Key features of the solution include:
- Simplified and Automated Approach: EVERSANA’s solution seamlessly integrates automation, AI, data, analytics, and human involvement to simplify pharmacovigilance processes.
- Regulatory Compliance and Financial Impact: The solution ensures regulatory compliance while optimizing resource allocation, processing speeds, and reducing costs per case, resulting in positive financial outcomes.
- Reduced Risk with Flexibility: EVERSANA’s solution is flexible, catering to the specific needs of each organization and product life cycle phase, thus minimizing the risk associated with switching vendors.
- High-Tech, High-Touch Approach: The solution leverages both AI and human interaction to offer an advanced and personalized approach to pharmacovigilance, distinguishing it from vendors that primarily offer automation.
- Comprehensive Integration of PV Services: The solution integrates various pharmacovigilance services, including automated case processing, aggregate reporting, signal detection, literature monitoring, translations and Qualified Person for Pharmacovigilance (QPPV) services.
- Automated Data Processing: The solution automates a significant portion of the data processing tasks, including regulatory authority cases, forms, articles/email complaints, literature monitoring, data migration, validity checks, and reporting. Human intervention is limited to translation, quality checks, and medical reviews.
- Efficiency Improvements: The solution leads to quicker processing times (3-5 days compared to 10 days) and reduces the cost per case by 50%.
- Proven Capabilities: EVERSANA’s solution has been implemented with five clients and validated through testing and hazard analysis. It utilizes machine learning benchmarks like Precision, Recall, and F1 Scores for reliability.
- Global Execution and Flexibility: The solution is adaptable to companies of all sizes and disease states, making it suitable for a wide range of organizations. It covers various stages of the product life cycle, including Pre-Clinical, Clinical Phase, Launch Readiness, and Post-Product Launch.
About the World Drug Safety Congress EU
The World Drug Safety Congress Europe, the meeting place for innovators and leaders in the drug safety sector to meet and shape the future of the pharmacovigilance, will bring together 1500+ key thought leaders to explore key challenges in pharmacovigilance. From exploring the use of big data and AI in pharmacovigilance to examining benefit-risk management strategies and patient centric approaches, drug safety is at the forefront of innovative technologies that will have an impact on the lives of patients.